Brain-Scan-Guided TMS for Depression

When you are living with depression, unfamiliar treatment language can create both hope and uncertainty. Terms such as “personalized TMS” and “brain-scan-guided treatment” may sound reassuring, but they also raise important questions: What is being personalized? Does imaging improve outcomes? What happens afterward?

At Avalon Malibu, we believe education should make care easier to understand—not make anyone feel pressured to choose the newest technology. Our approach to depression care centers on individualized treatment planning. This question-and-answer guide explains what scan-guided targeting means, where the evidence is encouraging, and why assessment and follow-up remain essential.

What is TMS, and what does it target?

Transcranial magnetic stimulation, or TMS, is a noninvasive treatment that uses a magnetic coil positioned against the scalp to stimulate nerve cells in selected brain regions. Repetitive TMS delivers repeated pulses, usually to an area involved in mood regulation. It does not require surgery or anesthesia, and the person remains awake during treatment.

TMS has evidence supporting its use for depression, particularly when previous medication treatment has not provided adequate relief or has been difficult to tolerate. However, there is no single treatment experience or outcome that applies to everyone. The National Institute of Mental Health’s explanation of brain stimulation therapies describes both its clinical role and ongoing questions about targeting and sustained improvement.

How does standard targeting differ from scan-guided targeting?

“Targeting” means deciding where to position the coil. Conventional approaches use measurements on the head to estimate the location of the intended brain region. These include fixed-distance methods and scalp-measurement approaches, such as Beam F3, that account for head size and shape. Standard targeting is not simply guesswork.

Imaging-guided approaches use information from an individual’s MRI scan. A navigation system can help clinicians align the coil with a location identified on that person’s brain images. Anatomical navigation supports more consistent positioning, while connectivity-guided targeting adds information about relationships between brain regions.

Another term is intermittent theta-burst stimulation, or iTBS. This is a form of TMS that delivers magnetic pulses in a particular burst pattern. It describes how stimulation is delivered, not how the target is selected. Scan guidance, pulse pattern, and treatment schedule are separate features; knowing one does not tell you the others. A clinical guide published in the American Journal of Psychiatry explains these distinctions and the limitations of existing targeting methods.

Is brain-scan-guided treatment always better?

No. “Scan-guided” covers different methods, and more individualized positioning does not automatically guarantee better or longer-lasting symptom relief.

Two approaches under investigation are:

• Structural-connectivity guidance: Uses imaging to estimate physical pathways connecting brain regions.
• Functional-connectivity guidance: Uses imaging to assess relationships between activity patterns in different brain regions.

A double-blind randomized trial involving 123 adults found that structural-connectivity-guided iTBS produced greater depression-score improvement than conventional five-centimeter scalp targeting at two weeks; both imaging-guided approaches performed better at six weeks. By twelve weeks, differences between groups were no longer statistically significant.

This was a single-center study using a particular treatment protocol and comparator—not a test of every scan-guided approach against every conventional method. The absence of a significant difference at twelve weeks also does not mean everyone’s improvement disappeared. The trial’s findings on individualized connectivity-guided targeting support cautious optimism, not a promise of superiority.

For us, the practical takeaway is that technical precision and meaningful recovery are related questions, but they are not interchangeable.

Can a brain scan replace a mental health assessment?

No. Selecting a stimulation location is different from understanding someone’s diagnosis and treatment needs. Symptoms, medical history, previous care, and changes in mood over time remain central to assessment.

This matters when distinguishing major depression from depression associated with bipolar disorder. A person may remember depressive episodes clearly while overlooking periods of unusually elevated mood or energy. The NIMH guidance on bipolar disorder assessment explains that diagnosis depends on symptoms and experiences across a person’s lifetime, rather than current depression alone.

Within our residential mental health treatment approach, we emphasize comprehensive evaluation and ongoing clinical review. Personalization should include the person’s experiences, needs, and goals—not only imaging data. This article does not indicate that we provide a particular TMS device, imaging method, or stimulation protocol.

How do clinicians assess suitability and safety?

Suitability is not determined by a scan alone. A clinical evaluation considers the nature of the depression, previous treatment, medical conditions, and potential risks.

Important assessment areas include:

• Current medications, supplements, and relevant treatment history.
• Seizure history and neurological illness or injury.
• Implanted devices or metal that could affect safety.
• Pregnancy and other medical considerations.
• Bipolar symptoms, psychosis, and alcohol or drug use.

These factors do not all automatically rule out treatment. Their significance requires individualized clinical judgment.

Common TMS side effects include scalp discomfort, headache, facial muscle twitching, and lightheadedness. Serious adverse effects are uncommon but can include seizures, mania, and hearing injury without adequate protection. Imaging guidance does not remove the need for safety screening, hearing protection, or monitoring. Mayo Clinic’s overview of TMS preparation and risks outlines these considerations.

A responsible assessment should leave room for uncertainty and preferences, rather than treating eligibility as an obligation to proceed.

What might the brain scan itself involve?

MRI is a separate procedure from TMS. It uses magnetic fields and radio waves to create images; it does not use ionizing radiation. During a brain MRI, the person typically lies inside the scanner and needs to remain still. The machine can be noisy, and an enclosed space may feel uncomfortable.

MRI also requires its own screening for implanted devices and metal. The imaging team needs relevant safety information even when a separate treatment team has already collected a medical history. Mayo Clinic’s brain MRI guide describes the procedure and safety considerations.

Comfort, accessibility, and the practical burden of imaging deserve attention alongside the technical rationale.

What should follow-up involve?

A treatment plan needs a way to evaluate progress—not just a location for the coil. Clinical monitoring commonly combines symptom-rating scales with conversations about changes in daily life and any adverse effects.

Useful areas to review include:

• Depression symptoms compared with the starting point.
• Sleep, energy, concentration, and everyday functioning.
• Side effects or unexpected mood changes.
• Whether improvement continues after the initial treatment course.
• How ongoing care is coordinated among clinicians.

Some plans include continuation or maintenance TMS, meaning additional sessions after an initial course. However, research has not established one optimal maintenance schedule for everyone. An expert consensus update on TMS care and monitoring emphasizes tracking clinical response and identifies uncertainties around maintaining benefits.

We believe success should be discussed in terms that matter to the individual. Returning to responsibilities, feeling more connected, or finding daily life more manageable may be meaningful goals alongside changes on a questionnaire. Follow-up should make space for those goals without promising that any particular treatment will achieve them.

What information supports an informed decision?

For someone already evaluating a treatment proposal, informed consent should explain the plan rather than simply label it “personalized.” A clear discussion can address:

• What exactly is being individualized: positioning, connectivity, stimulation pattern, or schedule?
• What evidence supports this particular approach, and what remains uncertain?
• How will progress and side effects be assessed?
• What are the practical commitments and expected costs?
• Who is responsible for follow-up and communication with other treating clinicians?
• What happens if symptoms do not improve or return?

These questions are about understanding a proposal, not requesting a specific treatment. They can also help distinguish a thoughtful clinical explanation from marketing language.

You deserve an explanation that allows time for reflection and respects your preferences. A technically detailed plan should still be understandable in everyday language.

Keeping the whole person at the center

Brain-scan guidance may refine one part of depression treatment. It should not overshadow the importance of assessment, realistic expectations, and continuing support.

At Avalon Malibu, our aftercare planning includes individualized transition plans and connections with community professionals and resources. We view coordination and continuity as part of personalized care, regardless of the treatments involved.

If you or someone you love needs support with depression or other mental health concerns, reach out to us at Avalon Malibu at 888-958-7511. We can discuss your needs and our approach to care without assuming that one technology is the answer for everyone.